ClinicalTrials.gg
CompletedNCT05317494SURVIVEUpdated Oct 2, 2026

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece

An observational study in Acute Myeloid Leukemia, sponsored by AbbVie. Completed at 13 sites in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by AbbVie · Observational

How we know

Updated Oct 2, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
106
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Leukemia, Myeloid, Acute by AbbVie — 4 open to participants now, 9 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · AbbVie.

Enrollment
6th of 10
106 · median 113
Started
2022
with 2 others
Observational
10 of 43
1 open now
Registered
34th of 43
by date

Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 6th largest by enrollment of the 10 observational ones that give a count, is one of 3 that started in 2022, is one of 10 observational ones, and was the 34th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 43 studies in Leukemia, Myeloid, Acute by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Leukemia, Myeloid, Acute by AbbVie, or all of them as a file.
02

Study summary

Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for intensive chemotherapy in Greece.

Venetoclax is a drug approved to treat Acute Myeloid Leukemia. All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive chemotherapy will be enrolled.

Around 100 participants will be enrolled in the study in approximately 15 sites in Greece.

Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 30 months.

There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 30 months.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Acute Myeloid Leukemia
  • Venetoclax
  • Venclexta
  • Venclyxto
  • ABT-199
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants with acute myeloid leukemia (AML) treated with venetoclax per approved local label in Greece.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant diagnosed Acute Myeloid Leukemia (AML) who is ineligible to intensive chemotherapy and is eligible to receive venetoclax as a therapy, as per Greek Ministry of Health (MOH) label.
  • Physician has decided to initiate venetoclax treatment. The decision to treat with venetoclax is made by the physician in accordance with the local label prior to any decision to approach the patient to participate in this study.

Exclusion criteria

Exclusion Criteria:

- Participating in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
106 participants (actual)

Groups and cohorts

  • Venetoclax Participants

    Participants treated with Venetoclax in accordance with approved local label.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Overall Survival (OS)

    OS is defined as the time from treatment initiation to death from any cause.

    Time frame: Up to 30 Months

Secondary outcomes

  1. Percentage of Participants Achieving Composite Complete Remission

    Composite complete remission is defined as the proportion of participants with complete remission (CR) or complete remission with incomplete marrow recovery (CRi).

    Time frame: Up to 30 Months

  2. Total Time of Treatment with Venetoclax Combination Therapy

    The total time of treatment with venetoclax combination therapy.

    Time frame: Up to 30 Months

  3. Time to Transfusion Independence

    Total duration of transfusion independence is defined as the period of at least 56 days with no Red Blood Cell (RBC) or platelet transfusion between the first dose of study drug and the last dose of study drug plus 30 days.

    Time frame: Up to 30 Months

  4. Post Baseline RBC and Platelet Transfusion Independence Rate

    Post baseline RBC and platelet transfusion independence rate will be calculated as the proportion of participants who achieved RBC and platelet, respectively, transfusion independence post baseline.

    Time frame: Up to 30 Months

  5. Change from Baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) Considered Minimally Clinical Important

    The EQ-5D-5L is a standardized instrument used to measure health-related quality of life that can be used in a wide range of health conditions and treatments.

    Time frame: Up to 30 Months

  6. Treatment Patterns Venetoclax in Combination with Hypomethylating Agents (HMAs)

    Treatment patterns defined by the proportion of participants treated with venetoclax in combination with HMAs (dosing with venetoclax and any modifications/interruptions/titrations, type and dosing of each HMA, frequency of response assessment, cycle length, dosing, concomitant medications, etc).

    Time frame: Up to 30 Months

  7. Healthcare Resource Utilization as the Number of Transfusions (Red Blood Cell [RBC] or Platelets) Received during First-line Treatment in an Outpatient Setting

    Healthcare resource utilization as the number of transfusions (red blood cell \[RBC\] or platelets) received during first-line treatment in an outpatient setting.

    Time frame: Up to 30 Months

  8. Healthcare Resource Utilization as the Number of Hospitalizations during First-line Treatment

    Healthcare resource utilization as the number of hospitalizations during first-line treatment.

    Time frame: Up to 30 Months

  9. Healthcare Resource Utilization as the Number of Intensive Care Unit (ICU) Admissions during First-line Treatment

    Healthcare resource utilization as the number of intensive care unit (ICU) admissions during first-line treatment.

    Time frame: Up to 30 Months

  10. Healthcare Resource Utilization as the Number of Visits in a Private Healthcare Practitioner

    Healthcare resource utilization as the number of visits in a private healthcare practitioner.

    Time frame: Up to 30 Months

  11. Healthcare Resource Utilization as the Name of Relevant Medication due to Infections (Antibiotics or Other)

    Healthcare resource utilization as the name of relevant medication due to infections (antibiotics or other).

    Time frame: Up to 30 Months

  12. Healthcare Resource Utilization as the Dosing Scheme of Relevant Medication due to Infections (Antibiotics or Other)

    Healthcare resource utilization as the dosing scheme of relevant medication due to infections (antibiotics or other).

    Time frame: Up to 30 Months

  13. Healthcare Resource Utilization as the Number of Laboratory Tests

    Healthcare resource utilization as the number of laboratory tests.

    Time frame: Up to 30 Months

  14. Healthcare Resource Utilization as the Type of Laboratory Tests

    Healthcare resource utilization as the type of laboratory tests.

    Time frame: Up to 30 Months

07

Study locations

13 sites
  • Olympion General Clinic /ID# 268392
    Pátrai, Achaia 26443, Greece
  • General Hospital of Athens Gennimatas /ID# 245968
    Athens, Attica 11527, Greece
  • General Hospital of Athens Laiko /ID# 244338
    Athens, Attica 11527, Greece
  • University General Hospital Attikon /ID# 248265
    Chaïdári, Attica 12462, Greece
  • University General Hospital of Heraklion PA.G.N.I /ID# 244337
    Heraklion, Crete 71500, Greece
  • General University Hospital of Alexandroupolis /ID# 244235
    Alexandroupoli, 68100, Greece
  • General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 244339
    Athens, 10676, Greece
  • General Anti-cancer Hospital Agios Savvas /ID# 244408
    Athens, 11522, Greece
  • General Hospital of Athens Laiko - Hematology Location /ID# 244234
    Athens, 11527, Greece
  • University General Hospital of Ioannina /ID# 244336
    Ioannina, 45500, Greece
  • University General Hospital of Patras /ID# 244335
    RION Patras Achaia, 26504, Greece
  • Papageorgiou General Hospital /ID# 248266
    Thessaloniki, 56429, Greece
  • General Hospital of Thessaloniki George Papanikolaou /ID# 244237
    Thessaloniki, 57010, Greece
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in May 2026, 48 months.

Of 160 observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 154. This study's 48 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2026 → May 2026 and completion Dec 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2022
First posted
Apr 7, 2022
StartActual
May 26, 2022
Primary completionActual
May 29, 2026was Dec 2026
CompletionActual
May 29, 2026was Dec 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 2, 2026
Sites
1 site added, 1 site removed
Show site
  • University General Hospital Attikon /ID# 248265 · Chaïdári, Greece
Show 1 removed
  • University General Hospital Attikon /ID# 248265 · Athens, Greece
Oct 2, 2026
Primary completion
Dec 2026→May 29, 2026 (actual)
Oct 2, 2026
Study completion
Dec 2026→May 29, 2026 (actual)
Oct 2, 2026
Enrollment
100 (estimated)→106 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • University General Hospital Attikon /ID# 248265 · Chaïdári, Greece
    Show 1 removed
    • University General Hospital Attikon /ID# 248265 · Athens, Greece
    Primary completion Dec 2026→May 29, 2026 (now actual)
    Study completion Dec 2026→May 29, 2026 (now actual)
    Enrollment 100 (estimated)→106 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05317494
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 7, 2022
Start date
May 26, 2022
Primary completion
May 29, 2026
Completion
May 29, 2026
Last update
Oct 2, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion